We sat down with Pro Medicus CEO, Dr Sam Hupert on results day to discuss the past six months and the all-important outlook.

Welcome to the second weekly report for the February 2025 results season. The FNArena Reporting Season Monitor reports ...

Earnings season divides winners and losers as rate cut bets shift and US inflation rattles markets.

Despite sky-high valuations, Jun Bei Liu is bullish on Pro Medicus. She first bought at $25 - now it’s 10x’d. How much higher ...

When it comes to investing in gold, many investors are faced with a choice: physical gold or gold mining stocks. While both ...

Yarra Capital's Roy Keenan is a fixed income tragic, with 40+ years in the chair. Here, he shares his take on today's key ...

A new year with old themes. Strong absolute returns and the stocks which have benefited most from multiple divergence in 2024 ...

AI is a long-term growth story which will support the global economy and provide a wide range of potential investment ...

Its impact upon stocks – and of stocks upon it – has long been scant. Investors should ignore it and those who try to predict its actions.

February earnings season is here, and it could be make or break for beaten down stocks in the ASX Energy sector like Woodside ...

In this wire, Pzena Investment Management share where they find value-oriented opportunities in a mega cap-driven market.

This episode is all about Telstra ( ASX: TLS ), Australia’s leading telecommunications provider which has over 50% market ...